Alert: update to Pure Tech Health

5th September 2019 | Eoin Treacy

Action to take: introduce a stop at 250p
Originally recommended at: 155p
Currently trading at: 290p
Stop at: 250p

I received this email from a subscriber relating to PureTech Health:

You made a second recommendation on 18th May 2018 to buy PRTC with a 12-month upside target of £2.50. It is now trading at £2.76. Why have you not made the recommendation to sell? If you have changed your mind about the upside target then I think that should be communicated to your readers. Or am I missing something here?

I want to reassure you that I have not forgotten about the share, rather the opposite. My initial target was indeed 250p and I am pleased to see the share consolidate above that level. My investment thesis with PureTech has always been that it has so much going for it, that it only had to have one of its investments to go right for the share to take off.

That is what happened with the speculation the company will seek a US IPO following the positive FDA trajectory for its digital medicine product. Peel Hunt now has a 380p target for the share.

Therefore, I am not going to take the profit now. Instead I recommend introducing a stop at 250p. In the investment world it is often you let winners run and that it what I intend to do with PureTech.

All the best,


Eoin Treacy
Investment Director, Frontier Tech Investor

Subscribe Now
Show Sitemap
PUBLICATIONS
USEFUL LINKS
SOUTHBANK INVESTMENT RESEARCH

You don’t need more information to be a better, more profitable investor. You need better research. Here you’ll find investment ideas and strategies from some of Britain’s most experienced investors produced specifically for investors like you. Learn more about independent stock market research and advice from one of the UK’s oldest financial publishers.

  • Save
  • Print

Important Risk Warning

Advice in Altucher’s Investment Network Pro UK does not constitute a personal recommendation.

Any advice should be considered in relation to your own circumstances, risk tolerance and investment objectives. Before investing you should carefully consider the risks involved, including those described below. If you have any doubt as to suitability or taxation implications, seek independent financial advice.

General – Your capital is at risk when you invest, never risk more than you can afford to lose. Past performance and forecasts are not reliable indicators of future results. Bid/offer spreads, commissions, fees and other charges can reduce returns from investments. There is no guarantee dividends will be paid.

Small cap shares - Shares recommended may be small company shares. These can be illiquid meaning they are hard to trade and can have a large bid/offer spread. If you need to sell soon after you bought, you might get back less that you paid. This makes them riskier than other investments in larger share companies.

Overseas investments - Shares may be denominated in a currency other than sterling. The return from these may increase or decrease as a result of currency fluctuations. Any dividends will be taxed at source in the country of issue.

Unregulated investments - The Financial Conduct Authority does not regulate certain activities, including the buying and selling of commodities. This means that you will not have the protection of the Financial Ombudsman Service or the Financial Services Compensation Scheme.

Taxation – Profits from share dealing are a form of income and subject to taxation. Tax treatment depends on individual circumstances and may be subject to change.

Managing Editor: Sam Volkering. Editors or contributors may have an interest in shares recommended. Information and opinions expressed do not necessarily reflect the views of other editors/contributors of Southbank Investment Research Limited.

Full details of our complaints procedure, privacy policy and terms and conditions can be found at, www.southbankresearch.com.

Altucher’s Investing Network PRO UK is published in the UK with licenced content from Paradigm Press LLC. It contains regulated content and is issued by Southbank Investment Research Limited. Registered in England and Wales No 9539630. VAT No GB629 7287 94. Registered Office: Basement, 95 Southwark Street, London, SE1 0HX.

Contact Us: To contact customer services, please call us on 0203 966 4580, Monday to Friday, 10.00am – 5.00pm.

Southbank Investment Research Limited is authorised and regulated by the Financial Conduct Authority. FCA No 706697. https://register.fca.org.uk/.

© 2025 Southbank Investment Research Limited.

Registered in England Company No 9539630. VAT No GB629 7287 94. Registered Office: Basement, 95 Southwark Street, London SE1 0HX.

Southbank Investment Research Limited is authorised and regulated by the Financial Conduct Authority. FCA No 706697 https://register.fca.org.uk/

© 2026 Southbank Investment Research Ltd.